| ID | 1056 |
| Name of the vaccine | Pentaxim |
| Microbe | Bacteria |
| Disease name | Pertussis (Whooping Cough) |
| Name of bacteria | Bordetella pertussis |
| Type of vaccine | Combination |
| Nucleic acid content | DNA |
| Age | From 2 months |
| Description of the vaccine | Adsorbed diphtheria, tetanus, pertussis (acellular component), inactivated poliomyelitis and Haemophilus influenzae type b conjugate vaccine. |
| Name of the manufacturer | Sanofi Pasteur Ltd |
| Name of the manufacturing country | Thailand |
| Year of manufacture | 1997 |
| Clinical Phase status | Approved |
| Bacterial strain | Gram-negative coccobacillus. |
| Efficacy | The seroconversion rate was 83.9–100% for pertussis antigens (anti-PT and anti-FHA). |
| Vaccine formulation | Powder and suspension |
| Dosage | Two injections at 2 and 4 months of age and a booster at the age of 11 months OR three injections, gap of 1 to 2 months and booster within the second year of life. |
| Mechanism of action | NA |
| Route of administration | Intramuscular |
| Indications | Immunization against diphtheria, tetanus, acellular pertussis, inactivated poliomyelitis and Hib. |
| Export | Marketing Authorisation Holder: Sanofi Pasteur SA, France |
| Approval | European Union Pharmacopoeia |
| Adjuvant | Aluminium hydroxide |
| Repurposing | For diphtheria, tetanus, acellular pertussis, inactivated poliomyelitis and Hib. |
| Side effects of vaccine | Injection site redness, swelling, pain, fever, vomiting, irritability, abnormal crying, nervousness, loss of appetite, somnolence. |
| Post vaccination | NA |
| Dose type | Combination doses |
| Interspecies transfer | NA |
| PubMed identifier | 21749196 |
| Clinical trial number | NA |
| Reference | https://www.fda.moph.go.th/sites/drug/Shared%20Documents/Vaccine/U1DR2C1062470002211C-SPC.pdf |
| Other name | NA |
| Additional Links | NA
|